Annual Report 2015

MagForce AG is a pioneer in the area of nanotechnology-based cancer treatment. It is the first company
in the world to receive European approval for a medical product using nanoparticles. In Germany, this
innovative therapy is available to patients at the NanoTherm™ therapy centers at the Charité-Universitäts-
medizin hospital in Berlin, and the university hospitals Münster, Kiel, Cologne and Frankfurt. Additional
therapy centers in Germany are planned.


In March 2014, MagForce AG has incorporated an US affiliate, MagForce USA Inc., based in Nevada
to develop NanoTherm™ therapy for the treatment of glioblastoma and prostate cancer in the US and later
to introduce it to the US market.